DIAR6
MCID: DRR009
MIFTS: 46

Diarrhea 6 (DIAR6)

Categories: Gastrointestinal diseases, Genetic diseases, Oral diseases, Rare diseases

Aliases & Classifications for Diarrhea 6

MalaCards integrated aliases for Diarrhea 6:

Name: Diarrhea 6 56 73 29 13 6 71
Diar6 56 73
Chronic Infantile Diarrhea Due to Guanylate Cyclase 2c Overactivity 58
Diarrhea, Type 6 39
Diarrhea 43

Characteristics:

Orphanet epidemiological data:

58
chronic infantile diarrhea due to guanylate cyclase 2c overactivity
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
diarrhea 6:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

OMIM 56 614616
OMIM Phenotypic Series 56 PS214700
MeSH 43 D003967
ICD10 via Orphanet 33 P78.3
Orphanet 58 ORPHA314373
UMLS 71 C3553270

Summaries for Diarrhea 6

OMIM : 56 Diarrhea-6 is a relatively mild, early-onset chronic diarrhea that may be associated with increased susceptibility to inflammatory bowel disease, small bowel obstruction, and esophagitis (Fiskerstrand et al., 2012). For a discussion of genetic heterogeneity of diarrhea, see DIAR1 (214700). (614616)

MalaCards based summary : Diarrhea 6, also known as diar6, is related to meconium ileus and diarrhea 2, with microvillus atrophy. An important gene associated with Diarrhea 6 is GUCY2C (Guanylate Cyclase 2C). The drugs Pinaverium and Carboprost tromethamine have been mentioned in the context of this disorder. Affiliated tissues include colon, breast and lung, and related phenotypes are abdominal pain and vitamin b12 deficiency

UniProtKB/Swiss-Prot : 73 Diarrhea 6: A relatively mild, early-onset chronic diarrhea that may be associated with increased susceptibility to inflammatory bowel disease, small bowel obstruction, and esophagitis.

Related Diseases for Diarrhea 6

Diseases in the Diarrhea family:

Diarrhea 6 Diarrhea 9
Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity Inflammatory Diarrhea
Acute Diarrhea Congenital Diarrhea

Diseases related to Diarrhea 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1221)
# Related Disease Score Top Affiliating Genes
1 meconium ileus 28.8 GUCY2C C12orf60
2 diarrhea 2, with microvillus atrophy 12.7
3 diarrhea 5, with tufting enteropathy, congenital 12.7
4 diarrhea 1, secretory chloride, congenital 12.7
5 diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies 12.7
6 diarrhea 4, malabsorptive, congenital 12.6
7 congenital chloride diarrhea 12.6
8 acute diarrhea 12.6
9 diarrhea 8, secretory sodium, congenital 12.6
10 diarrhea 11, malabsorptive, congenital 12.6
11 diarrhea 9 12.5
12 secretory diarrhea 12.5
13 osmotic diarrhea 12.5
14 congenital diarrhea 12.5
15 inflammatory diarrhea 12.5
16 diarrhea 10, protein-losing enteropathy type 12.4
17 trichohepatoenteric syndrome 1 12.4
18 congenital diarrhea 7 with exudative enteropathy 12.4
19 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 12.4
20 diarrhea 7, protein-losing enteropathy type 12.3
21 motility-related diarrhea 12.3
22 functional diarrhea 12.3
23 diarrhea, chronic, with villous atrophy 12.3
24 secretory diarrhea, myopathy, and deafness 12.3
25 diarrhea, glucose-stimulated secretory, with common variable immunodeficiency 12.2
26 intractable diarrhea-choanal atresia-eye anomalies syndrome 12.1
27 genetic intractable diarrhea of infancy 12.1
28 syndromic congenital sodium diarrhea 12.1
29 chronic diarrhea due to glucoamylase deficiency 12.1
30 hemolytic uremic syndrome, atypical 1 12.0
31 satoyoshi syndrome 12.0
32 pancreatic cholera 11.9
33 vipoma 11.9
34 chronic diarrhea due to guanylate cyclase 2c overactivity 11.9
35 cholera 11.7
36 gastroenteritis 11.7
37 irritable bowel syndrome 11.7
38 glucose/galactose malabsorption 11.6
39 cryptosporidiosis 11.6
40 shigellosis 11.6
41 salmonellosis 11.5
42 celiac disease 1 11.5
43 lactose intolerance 11.5
44 ulcerative colitis 11.5
45 crohn's disease 11.5
46 collagenous colitis 11.5
47 acrodermatitis enteropathica, zinc-deficiency type 11.5
48 chylomicron retention disease 11.5
49 hemolytic-uremic syndrome 11.5
50 zollinger-ellison syndrome 11.5

Graphical network of the top 20 diseases related to Diarrhea 6:



Diseases related to Diarrhea 6

Symptoms & Phenotypes for Diarrhea 6

Human phenotypes related to Diarrhea 6:

31
# Description HPO Frequency HPO Source Accession
1 abdominal pain 31 occasional (7.5%) HP:0002027
2 vitamin b12 deficiency 31 occasional (7.5%) HP:0100502
3 diarrhea 31 HP:0002014

Symptoms via clinical synopsis from OMIM:

56
Abdomen Gastrointestinal:
abdominal pain (in some patients)
diarrhea, chronic, early-onset mild
dehydration in infancy (in some patients)
metabolic acidosis in infancy (in some patients)
electrolyte disturbances in infancy (in some patients)
more
Metabolic Features:
metabolic acidosis in infancy (in some patients)
electrolyte disturbances in infancy (in some patients)

Laboratory Abnormalities:
vitamin b12 deficiency (in some patients)

Abdomen External Features:
meteorism (gaseous distention of the stomach or intestine)

Genitourinary Ureters:
urolithiasis (in some patients)

Clinical features from OMIM:

614616

Drugs & Therapeutics for Diarrhea 6

Drugs for Diarrhea 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 923)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pinaverium Approved Phase 4 59995-65-2
2
Carboprost tromethamine Approved Phase 4 58551-69-2 5284525 35023177
3
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
4
Cobicistat Approved Phase 4 1004316-88-4
5
Donepezil Approved Phase 4 120014-06-4 3152
6
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
7
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
8
Rilpivirine Approved Phase 4 500287-72-9
9
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
10
Metformin Approved Phase 4 657-24-9 14219 4091
11
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
12
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
13
Calcium carbonate Approved, Investigational Phase 4 471-34-1
14
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
15
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
16
Sulfamethoxazole Approved Phase 4 723-46-6 5329
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Alverine Approved, Investigational Phase 4 150-59-4 3678
19
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
20
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
21
Dimenhydrinate Approved Phase 4 523-87-5 441281
22
Ondansetron Approved Phase 4 99614-02-5 4595
23
Linaclotide Approved Phase 4 851199-59-2 65351
24
Lopinavir Approved Phase 4 192725-17-0 92727
25
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
26
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
27
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
28
Aminophylline Approved Phase 4 317-34-0 9433
29
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
30
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
31
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
32
Ibuprofen Approved Phase 4 15687-27-1 3672
33
Insulin aspart Approved Phase 4 116094-23-6 16132418
34
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
35
Gliclazide Approved Phase 4 21187-98-4 3475
36
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
37
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
38
Polyestradiol phosphate Approved Phase 4 28014-46-2
39
Methylene blue Approved, Investigational Phase 4 61-73-4
40
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
41
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
42
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
43
Sorbitol Approved Phase 4 50-70-4 5780
44
Pantoprazole Approved Phase 4 102625-70-7 4679
45
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
46
Ledipasvir Approved Phase 4 1256388-51-8 67505836
47
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
48
Tranexamic Acid Approved Phase 4 1197-18-8 5526
49
Galantamine Approved Phase 4 357-70-0 9651
50
Propranolol Approved, Investigational Phase 4 525-66-6 4946

Interventional clinical trials:

(show top 50) (show all 2309)
# Name Status NCT ID Phase Drugs
1 The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial Unknown status NCT01792739 Phase 4 Lactobacillus casei variety rhamnosus granules;Placebo
2 Bacillus Particles Prevent More Children's Antibiotic-associated Diarrhea (AAD), Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT02993419 Phase 4 Bacillus licheniformis Intervention
3 Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle Unknown status NCT01469273 Phase 4 Mutaflor® Suspension
4 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
5 Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
6 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
7 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
8 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
9 Phase 4 Study of Effects of Dexmedetomidine on Prevention of Side Effects of Hemabate in Cesarean Section Patients Unknown status NCT02220361 Phase 4 placebo;low dose dexmedetomidine;high dose dexmedetomidine
10 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
11 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
12 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
13 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
14 Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
15 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
16 Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines Against Non-typhoid Salmonellae Unknown status NCT02121145 Phase 4
17 Effect of Ramosetron on Postoperative Restoration of Bowel Motility After Gynecological Laparoscopic Surgery Unknown status NCT02849483 Phase 4 Ramosetron;Normal saline
18 Application of Pinaverium Bromide in the Treatment of Patients With Post-cholecystectomy Sphincter of Oddi Dysfunction (SOD): A Randomized, Controlled and Multicenter Clinical Study Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
19 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
20 Assessment of Analgesic Efficacy and Safety of Intravenous Hyoscine-N-Butylbromide in Patients With Abdominal Colic Associated With Acute Gastroenteritis; a Randomized, Double-blind, Placebo Controlled Study Unknown status NCT02508142 Phase 4 Hyoscine-N-Butylbromide
21 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
22 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
23 The Hypotensive Effect of Simvastatin in Hypertensive Patients: a Placebo-controlled Randomized Clinical Trial With 24-h Ambulatory Blood Pressure Monitoring Unknown status NCT02072382 Phase 4 Metformin;Placebo
24 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
25 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
26 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
27 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
28 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
29 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
30 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
31 Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range Unknown status NCT01424241 Phase 4 Sandostatin LAR
32 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
33 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
34 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
35 Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome Unknown status NCT03557788 Phase 4 Rifaximin Oral Tablet
36 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
37 Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema) Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
38 Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome Unknown status NCT03148444 Phase 4 cefalexin 500 mg qid or roxithromycin 150 mg bid
39 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
40 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Unknown status NCT03519568 Phase 4
41 STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea Completed NCT00050635 Phase 4 Sandostatin LAR Depot
42 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
43 Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Efficacy and Safety Completed NCT00447161 Phase 4 Bacillus Clausii Multi ATB Resist;Placebo
44 3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM) Completed NCT03441581 Phase 4 Eluxadoline
45 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
46 Efficacy of Diosmectite (Smecta®) in the Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomised, Double Blind, Placebo Controlled, Parallel Groups Study. Completed NCT00276328 Phase 4 Diosmectite (Smecta®)
47 Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis: A Double Blind Randomized, Placebo- Controlled Trial Completed NCT01657032 Phase 4
48 Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Under Six Months. Completed NCT01571856 Phase 4 Zinc Sulfate
49 A Post -Marketing Drug Evaluation(Phase IV Clinical Trial) to Study the Safety and Efficacy of Heweizhixie Capsule in Patients With Diarrhea Completed NCT02607176 Phase 4 Heweizhixie capsule
50 Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial Completed NCT02871908 Phase 4 Lactobacillus reuteri DSM 17938;Placebo

Search NIH Clinical Center for Diarrhea 6

Cochrane evidence based reviews: diarrhea

Genetic Tests for Diarrhea 6

Genetic tests related to Diarrhea 6:

# Genetic test Affiliating Genes
1 Diarrhea 6 29 GUCY2C

Anatomical Context for Diarrhea 6

MalaCards organs/tissues related to Diarrhea 6:

40
Colon, Breast, Lung, Testes, Prostate, Liver, Bone

Publications for Diarrhea 6

Articles related to Diarrhea 6:

(show top 50) (show all 127)
# Title Authors PMID Year
1
Familial diarrhea syndrome caused by an activating GUCY2C mutation. 56 6
22436048 2012
2
Use of ketogenic diet therapy in infants with epilepsy: A systematic review and meta-analysis. 61
32452537 2020
3
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. 61
32490554 2020
4
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. 61
32463152 2020
5
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. 61
32303539 2020
6
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. 61
31941830 2020
7
Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections. 61
31950069 2019
8
Lymphocytic esophagitis: An Australian (Queensland) case series of a newly recognized mimic of eosinophilic esophagitis. 61
31633045 2019
9
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. 61
30603911 2019
10
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. 61
30833272 2019
11
[Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study]. 61
31262109 2019
12
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. 61
31230047 2019
13
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. 61
30179569 2018
14
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. 61
29334603 2018
15
A comparative analysis of quality of life after postoperative intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for cervical cancer. 61
30829265 2018
16
Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. 61
29891609 2018
17
Enterotoxigenic Escherichia coli Adhesin-Toxoid Multiepitope Fusion Antigen CFA/I/II/IV-3xSTaN12S-mnLTG192G/L211A-Derived Antibodies Inhibit Adherence of Seven Adhesins, Neutralize Enterotoxicity of LT and STa Toxins, and Protect Piglets against Diarrhea. 61
29263112 2018
18
A Case of Mesenteric Cyst in a 4-Year-Old Child with Acute Abdominal Pain. 61
29302510 2017
19
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. 61
27858180 2017
20
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. 61
28109627 2017
21
Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. 61
27404403 2017
22
Cobimetinib. 61
27701080 2017
23
A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer. 61
31583301 2017
24
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study). 61
26778644 2016
25
The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. 61
27003816 2016
26
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. 61
26598548 2016
27
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). 61
26642810 2016
28
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. 61
26499900 2015
29
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. 61
25822310 2015
30
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. 61
25371323 2015
31
[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer]. 61
25877315 2015
32
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. 61
25037971 2015
33
DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. 61
25320100 2014
34
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). 61
24112786 2014
35
Non-polio enterovirus association with persistent diarrhea in children as revealed by a follow-up study of an Indian cohort during the first two years of life. 61
24954472 2014
36
Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. 61
24849768 2014
37
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. 61
24615777 2014
38
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. 61
24799054 2014
39
[Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma]. 61
24581125 2014
40
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. 61
23111359 2014
41
[Status of enterovirus infection in children with acute lower respiratory tract infection]. 61
23676941 2013
42
UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. 61
22934695 2013
43
Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. 61
23299774 2013
44
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. 61
23838576 2013
45
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy. 61
23060583 2012
46
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). 61
22634799 2012
47
Teething disturbances; prevalence of objective manifestations in children under age 4 months to 36 months. 61
22143712 2012
48
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. 61
21626051 2012
49
What palliative care-related problems do patients experience at HIV diagnosis? A systematic review of the evidence. 61
21620647 2011
50
Systematic review of health-related quality of life after esophagectomy for esophageal cancer. 61
22180708 2011

Variations for Diarrhea 6

ClinVar genetic disease variations for Diarrhea 6:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GUCY2C NM_004963.4(GUCY2C):c.2519G>T (p.Ser840Ile)SNV Pathogenic 30176 rs587776871 12:14775021-14775021 12:14622087-14622087
2 GUCY2C NM_004963.4(GUCY2C):c.1997A>G (p.Tyr666Cys)SNV Likely pathogenic 870487 rs562942379 12:14794087-14794087 12:14641153-14641153
3 GUCY2C NM_004963.4(GUCY2C):c.1540A>G (p.Ile514Val)SNV Likely pathogenic 870488 rs551796026 12:14804958-14804958 12:14652024-14652024

UniProtKB/Swiss-Prot genetic disease variations for Diarrhea 6:

73
# Symbol AA change Variation ID SNP ID
1 GUCY2C p.Ser840Ile VAR_067724 rs587776871

Expression for Diarrhea 6

Search GEO for disease gene expression data for Diarrhea 6.

Pathways for Diarrhea 6

GO Terms for Diarrhea 6

Sources for Diarrhea 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....